文献速递MDS 与骨髓增殖性肿瘤

GATA-1:鉴别原发性血小板增多症与骨髓纤维化的潜在新型生物标志物

GATA-1: A potential novel biomarker for the differentiation of essential thrombocythemia and myelofibrosis.
PubMed 文献 · J Thromb Haemost · 2019-04-25

研究比较36例原发性血小板增多症(ET)、14例骨髓纤维化(MF)患者及7名健康对照的外周血GATA-1、NFE2、FLI1表达,发现ET患者GATA-1 mRNA上调且不依赖治疗方案或突变状态,MF巨核细胞GATA-1蛋白染色减低,提示GATA-1或可用于ET诊断及与MF的鉴别。

要点

  • ET患者外周血GATA-1 mRNA上调,与治疗方案及突变状态无关。
  • MF患者骨髓巨核细胞GATA-1蛋白染色较ET患者减低。
  • FLI1表达显著下调,NFE2表达不受GATA-1 mRNA水平变化影响。

核心结论

  • 外周血结果证实了既往在ET患者全骨髓中观察到的GATA-1 mRNA升高。
  • GATA-1 mRNA水平独立于降细胞治疗,可能作为ET的诊断标志物及其与MF鉴别诊断的标志物。

研究设计与样本

  • 研究纳入36例ET患者、14例MF患者和7名健康对照供者,提取外周血单个核细胞总RNA,用定量聚合酶链反应测定基因表达相对变化。
  • 同时在ET和MF患者骨髓切片中测定GATA-1蛋白水平。

主要发现

  • ET患者GATA-1 mRNA上调,不论治疗方案或突变状态如何。
  • FLI1表达显著下调,而NFE2表达不受GATA-1 mRNA水平变化影响。
  • ET患者巨核细胞GATA-1蛋白水平较MF患者增高。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Essentials The BCR-ABL negative myeloproliferative neoplasms are subjected to unknown phenotypic modifiers. GATA-1 is upregulated in ET patients, regardless of treatment regimen or mutational status. Myelofibrosis (MF) megakaryocytes displayed decreased GATA-1 staining. GATA-1 may have utility as a diagnostic marker in ET and in its differential diagnosis from MF. ABSTRACT: Background The BCR-ABL-negative myeloproliferative neoplasms, i.e., polycythemia vera, essential thrombocythemia (ET), and myelofibrosis (MF), are characterized by mutations in JAK2, CALR, or MPL. However, an as yet unknown factor drives the precise disease phenotype. The hematopoietic transcription factor GATA-1 and its downstream targets NFE2 and FLI1 are responsible for determining erythroid and megakaryocyte lineages during hematopoietic stem cell differentiation. Previous studies have demonstrated a low level of GATA-1 expression in megakaryocytes from patients with MF. Objectives and methods The expression of GATA-1, NFE2 and FLI1 was studied for changes in the peripheral blood (PB) of ET patients. Peripheral blood samples were obtained from 36 ET patients, 14 MF patients, and seven healthy control donors. Total RNA from PB mononuclear cells (PBMCs) was extracted, and quantitative polymerase chain reaction was used to determine relative changes in gene expression. Protein levels of GATA-1 were also determined in bone marrow sections from ET and MF patients. Results GATA-1 mRNA was upregulated in ET patients, regardless of treatment regimen or mutational status. FLI1 expression was significantly downregulated, whereas NFE2 expression was unaffected by changes in GATA-1 mRNA levels. Megakaryocytes from ET patients showed increased protein levels of GATA-1 as compared with those from MF patients. Conclusions Our results confirmed, in PB, our previous data demonstrating elevated levels of GATA-1 mRNA in total bone marrow of ET patients. GATA-1 mRNA levels are independent of cytoreductive therapies, and may have utility as a diagnostic marker in ET and in its differential diagnosis from MF.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Lally J, Boasman K, Brown L, et al. GATA-1: A potential novel biomarker for the differentiation of essential thrombocythemia and myelofibrosis. J Thromb Haemost. 2019. PMID: 30889303. doi:10.1111/jth.14433

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。